CA2594215A1 - Sustained-release nanoparticle compositions and methods for using the same - Google Patents

Sustained-release nanoparticle compositions and methods for using the same Download PDF

Info

Publication number
CA2594215A1
CA2594215A1 CA002594215A CA2594215A CA2594215A1 CA 2594215 A1 CA2594215 A1 CA 2594215A1 CA 002594215 A CA002594215 A CA 002594215A CA 2594215 A CA2594215 A CA 2594215A CA 2594215 A1 CA2594215 A1 CA 2594215A1
Authority
CA
Canada
Prior art keywords
sustained
same
methods
release nanoparticle
nanoparticle compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002594215A
Other languages
French (fr)
Other versions
CA2594215C (en
Inventor
Vinod D. Labhasetwar
Sanjeeb K. Sahoo
Maram K. Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska
Original Assignee
The Board Of Regents Of The University Of Nebraska
Vinod D. Labhasetwar
Sanjeeb K. Sahoo
Maram K. Reddy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Nebraska, Vinod D. Labhasetwar, Sanjeeb K. Sahoo, Maram K. Reddy filed Critical The Board Of Regents Of The University Of Nebraska
Publication of CA2594215A1 publication Critical patent/CA2594215A1/en
Application granted granted Critical
Publication of CA2594215C publication Critical patent/CA2594215C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Abstract

The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N~alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.

Claims (3)

1. A sustained-release nanoparticle composition comprising a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol conjugate.
2. The sustained-release nanoparticle composition of claim 1, further comprising a therapeutic agent.
3. A method for preventing or treating a disease or condition comprising locally administering to a patient having or at risk of having a disease or condition, an effective amount of a composition of claim 2 thereby preventing or treating the disease or condition in the patient.
CA2594215A 2004-12-21 2005-12-12 Sustained-release nanoparticle compositions and methods for using the same Expired - Fee Related CA2594215C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/018,456 US7727554B2 (en) 2004-12-21 2004-12-21 Sustained-release nanoparticle compositions and methods for using the same
US11/018,456 2004-12-21
PCT/US2005/045010 WO2006068877A2 (en) 2004-12-21 2005-12-12 Sustained-release nanoparticle compositions and methods for using the same

Publications (2)

Publication Number Publication Date
CA2594215A1 true CA2594215A1 (en) 2006-06-29
CA2594215C CA2594215C (en) 2011-11-08

Family

ID=36596119

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2594215A Expired - Fee Related CA2594215C (en) 2004-12-21 2005-12-12 Sustained-release nanoparticle compositions and methods for using the same

Country Status (6)

Country Link
US (6) US7727554B2 (en)
EP (1) EP1827389A4 (en)
CN (1) CN101442991A (en)
AU (1) AU2005319495B2 (en)
CA (1) CA2594215C (en)
WO (1) WO2006068877A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US8312836B2 (en) * 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060088596A1 (en) 2004-09-28 2006-04-27 Atrium Medical Corporation Solubilizing a drug for use in a coating
US8858978B2 (en) 2004-09-28 2014-10-14 Atrium Medical Corporation Heat cured gel and method of making
US7727554B2 (en) * 2004-12-21 2010-06-01 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Sustained-release nanoparticle compositions and methods for using the same
US9427423B2 (en) * 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) * 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
CA2626030A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
BRPI0600285C1 (en) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda nanoparticulate pharmaceutical compounds useful for treating restenosis
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
MX2009010907A (en) 2007-04-13 2010-03-17 Univ North Texas Formulation of active agent loaded activated plga nanoparticles for targeted cancer nano-therapeutics.
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
US20100279289A1 (en) * 2007-05-24 2010-11-04 Fanqing Frank Chen Size-dependent biological effect of nanoparticles
WO2009020865A1 (en) * 2007-08-03 2009-02-12 The Board Of Regents Of The University Of Nebraska Surface-modified nanoparticles for intracellular delivery of therapeutic agents and composition for making same
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
KR20130100290A (en) 2010-08-30 2013-09-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Shear controlled release for stenotic lesions and thrombolytic therapies
EP2696887A4 (en) * 2011-04-15 2015-01-07 Univ California Redox responsive polymeric nanocapsules for protein delivery
CN103648521A (en) 2011-04-28 2014-03-19 阿布拉科斯生物科学有限公司 Intravascular delivery of nanoparticle compositions and uses thereof
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US20140100182A1 (en) 2012-10-05 2014-04-10 The Cleveland Clinic Foundation Nanogel-Mediated Drug Delivery
EP2953640B1 (en) 2013-02-07 2020-04-08 The Cleveland Clinic Foundation Nanoencapsulated superoxide dismutase and catalase for treating spinal cord injury
WO2015089268A1 (en) 2013-12-11 2015-06-18 University Of Massachusetts Compositions and methods for treating disease using salmonella t3ss effector protein (sipa)
US10517934B2 (en) 2014-08-25 2019-12-31 ProTransit Nanotherapy, LLC Compositions and methods for the treatment of photoaging and other conditions
CN104257633B (en) * 2014-08-27 2017-10-03 珠海健帆生物科技股份有限公司 Anti-freezing spansule and preparation method thereof, feature anti-freezing slow release device
WO2016168290A1 (en) 2015-04-13 2016-10-20 The Cleveland Clinic Foundation Nitric oxide synthase nanoparticles for treatment of vascular disease
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
US20210196932A1 (en) 2016-02-08 2021-07-01 Orbusneich Medical, Inc. Drug Eluting Balloon
CN108771656A (en) * 2018-07-10 2018-11-09 白晓春 Rapamycin sustained-release dosage type and preparation method, rapamycin it is slow-release injected and application
US11471412B1 (en) 2019-05-10 2022-10-18 University Of South Florida Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration
CN111973813A (en) * 2020-09-07 2020-11-24 乐普（北京）医疗器械股份有限公司 Rapamycin nanoparticle for porous balloon angioplasty
US20230355540A1 (en) 2020-09-29 2023-11-09 Oxford University Innovation Limited Stroke treatment
WO2022192361A2 (en) * 2021-03-09 2022-09-15 Board Of Regents Of The University Of Nebraska Microparticle compositions and methods use thereof
CN115517991B (en) * 2022-01-25 2024-03-22 西南医科大学 Three-agent type safe and nontoxic hair dye and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0914102T3 (en) * 1996-05-24 2006-01-09 Angiotech Pharm Inc Preparations and methods for treating or preventing diseases of the body canals
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
IN191203B (en) * 1999-02-17 2003-10-04 Amarnath Prof Maitra
WO2001087227A2 (en) * 2000-05-17 2001-11-22 Labopharm, Inc. Drug containing polymeric micelles
US6579519B2 (en) * 2000-09-18 2003-06-17 Registrar, University Of Delhi Sustained release and long residing ophthalmic formulation and the process of preparing the same
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US7727554B2 (en) * 2004-12-21 2010-06-01 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Sustained-release nanoparticle compositions and methods for using the same

Also Published As

Publication number Publication date
WO2006068877A2 (en) 2006-06-29
US20140050798A1 (en) 2014-02-20
US20100203153A1 (en) 2010-08-12
WO2006068877A3 (en) 2009-03-19
AU2005319495B2 (en) 2010-06-03
US20130089616A1 (en) 2013-04-11
EP1827389A2 (en) 2007-09-05
US20160030402A1 (en) 2016-02-04
CN101442991A (en) 2009-05-27
US20060134209A1 (en) 2006-06-22
US20170000742A1 (en) 2017-01-05
US7727554B2 (en) 2010-06-01
CA2594215C (en) 2011-11-08
EP1827389A4 (en) 2012-09-12
US9138416B2 (en) 2015-09-22
AU2005319495A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
CA2594215A1 (en) Sustained-release nanoparticle compositions and methods for using the same
EP1669364A3 (en) Methods and compositions for treating hepatitis C virus
WO2006055954A3 (en) Steroid formulation and methods of treatment using same
EP2335727A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
WO2004034975A3 (en) Sustained release profile modification
DE60316779D1 (en) THIADIAZOLYLPIPERAZINE DERIVATIVES SUITABLE FOR THE TREATMENT OF BZW. PREVENTION OF PAIN
EP1658849A3 (en) therapeutic combinations of antihypertensive and antiangiogenic agents
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2006083779A3 (en) Pharmaceutical composition comprising hydroxylated nebivolol
WO2005011734A3 (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2004028570A3 (en) A method for treating severe tinnitus
DE60327843D1 (en) MEDICAMENT FORMULATIONS WITH DELAYED RELEASE WITH A CARRIER PEPTIDE
RU2005126412A (en) COP1 FOR TREATMENT OF INFLAMMATORY DISEASES OF THE INTESTINE
WO2007056405A8 (en) Magnesium-containing polymers for the treatment of hyperphosphatemia
WO2002098464A3 (en) Liquid polymer composition for prevention and treatment of the oral cavity diseases
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
WO2002028372A3 (en) Systemic delivery of compounds through non-invasive bladder administration
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
JP2004537500A5 (en)
EP1393734A4 (en) Drugs for intestinal diseases
WO2002102743A3 (en) DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
WO2006122925A3 (en) Oral medicament based on a proton pump inhibitors
CA2313270A1 (en) Use of deferiprone in treating and preventing iron-induced cardiac disease

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191212